3 Firms Score End-Payor Co-Lead Role In Seroquel XR Cases
Law360 (November 13, 2020, 8:03 PM EST) -- A Delaware federal judge on Friday tapped three firms — Grant & Eisenhofer PA, Cohen Milstein Sellers & Toll PLLC and Shepherd Finkelman Miller & Shah LLP — to lead the proposed end-payor class accusing AstraZeneca of paying off generic-drug makers to protect its brand antipsychotic drug Seroquel XR.
U.S. District Judge Colm F. Connolly named the three firms as interim co-lead counsel for the proposed end-payor class, which alleges that AstraZeneca Pharmaceuticals LP struck deals with Handa Pharmaceuticals LLC, Par Pharmaceutical Inc. and Accord Pharmaceuticals Inc., inducing the generic-drug makers to hold off on launching their versions of Seroquel XR,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!